

HEALTHCARE-ACQUIRED INFECTION: DEVICES, PHARMACEUTICALS, AND ENVIRONMENTAL PRODUCTS



HLC092C
May 2015

Peggy Lehr
Project Analyst

ISBN: 1-62296-086-6



BCC Research
49 Walnut Park, Building 2
Wellesley, MA 02481 USA
866-285-7215 (toll-free within the USA),
or (+1) 781-489-7301
www.bccresearch.com
information@bccresearch.com

TABLE OF CONTENTS

TOPIC	PAGE NO.
CHAPTER 1 INTRODUCTION	2
REASONS FOR DOING THE STUDY	2
STUDY GOALS AND OBJECTIVES	2
SCOPE AND FORMAT	2
METHODOLOGIES AND INFORMATION SOURCES	3
ANALYST'S CREDENTIALS	3
RELATED BCC RESEARCH REPORTS	3
BCC RESEARCH WEBSITE	4
DISCLAIMER	4
CHAPTER 2 SUMMARY	6
<i>SUMMARY TABLE GLOBAL MARKET FOR SELECTED HAI TREATMENTS, THROUGH 2020 (\$ MILLIONS)</i>	8
<i>SUMMARY FIGURE GLOBAL MARKET SHARES OF HAI TREATMENTS BY GEOGRAPHICAL AREA, 2015 AND 2020 (%)</i>	8
CHAPTER 3 GLOBAL HAI OVERVIEW	11
RISKS FOR ACQUIRING HAI	11
MOST COMMON HEALTHCARE-ASSOCIATED INFECTIONS	12
<i>TABLE 1 CAUSES AND TYPES OF MOST COMMON HEALTHCARE-ACQUIRED INFECTIONS</i>	13
GRAM-POSITIVE BACTERIA	13
S. AUREUS	14
Transmission Routes	14
MRSA	14
Transmission Routes	15
PNEUMONIA	15
Pseudomonas Aeruginosa	15
Hospital-Acquired Pneumonia (HAP)	15
K. Pneumonia	15
CLOSTRIDIUM DIFFICILE	16
E. COLI	16
UTI Treatment Options	16
GASTROENTERITIS-CAUSING BACTERIA	17
Treatment Options	17
VANCOMYCIN-RESISTANT ENTEROCOCCI (VRE)	17
Types of VRE	17
LEGIONELLA BACTERIA	17
Treatment Options	18
GRAM-NEGATIVE BACTERIA	18
PSEUDOMONAS AERUGINOSA	18
ACINETOBACTER BAUMANNII	18
CARBAPENEM-RESISTANT ENTEROBACTERIACEAE (CRE)	19
VIRAL INFECTIONS	19
HEPATITIS C	19
Scope of Infection	19

TOPIC	PAGE NO.
Treatment	20
NOROVIRUS	20
INFLUENZA VIRUS	20
Influenza Virus A, B, C	20
Transmission	21
Symptoms	21
Treatment	21
FUNGAL INFECTIONS	21
MEDICAL NEED FOR ANTIFUNGALS	21
ASPERGILLUS INFECTIONS	22
Treatment	22
YEAST INFECTIONS	22
CANDIDA INFECTIONS	22
PREVENTING HAI	23
DETERMINING THE MODE OF TRANSMISSION	23
ROLES OF HEALTHCARE INSTITUTIONS AND INFECTION CONTROL INDIVIDUALS	23
<i>TABLE 2 SELECTED RESPONSIBILITIES OF INFECTION CONTROL TEAM MEMBERS</i>	24
COMPONENTS OF A HAI SURVEILLANCE SYSTEM	26
<i>TABLE 3 MAIN STEPS AND COMPONENTS IN DEVELOPING AN EFFECTIVE INFECTION CONTROL SURVEILLANCE SYSTEM</i>	26
HEALTHCARE INFECTION POINTS OF GENERATION	26
HOSPITAL	26
<i>FIGURE 1 OCCURRENCE OF HAI IN U.S. HOSPITALS BY TYPE, 2011 (%)</i>	27
Hospital Surgical Procedures	28
AMBULATORY SURGERY CENTERS IN THE U.S.	28
Infection Control in ASCs	28
DIALYSIS CENTERS	28
Transmission of VRE in Dialysis Centers	29
Hepatitis Transmission in Dialysis Centers	29
ASSISTED LIVING/LONG-TERM CARE FACILITIES	29
PROACTIVE TREATMENTS	30
THE IMPORTANCE OF HAND WASHING	30
CDC RECOMMENDATIONS FOR PREVENTION	30
<i>TABLE 4 CDC MEASURES FOR PREVENTION OF HEALTHCARE-ACQUIRED INFECTIONS</i>	30
<i>TABLE 5 PERCENTAGE DECREASE IN HAI IN U.S. HOSPITAL SETTINGS, 2008-2013 (%)</i>	32
ENVIRONMENTAL CONTROLS	32
DEVICE DESIGN	33
HUMAN AND MONETARY COSTS OF HAI	33
U.S. HEALTHCARE SPENDING	33
U.S. HEALTHCARE SPENDING ON HAI	33
<i>TABLE 6 ESTIMATED COSTS OF HAI IN U.S. HOSPITALS, 2012 (PER PATIENT OCCURRENCE) (\$)</i>	33
EMRA	34
JAPAN	34
RATE OF INFECTION	34

TOPIC	PAGE NO.
CHINESE MARKET	35
CHANGES IN THE HEALTHCARE INDUSTRY	35
<i>TABLE 7 SELECTED MERGERS AND/OR ACQUISITIONS, 2010-2015 (\$ MILLIONS)</i>	35
REGULATIONS	36
AMERICAS	36
Creating Drug Treatments	36
<i>TABLE 8 PROCESS OF CREATING DRUG TREATMENTS IN THE U.S.</i>	37
Infection Control Measures/Protocols	38
U.S. REGULATIONS	38
Hospital Infections Disclosure Act (HIDA)	38
Current and Pending Requirements	38
Affordable Care Act and Implications for the Pharmaceutical Industry	38
Biosimilars	39
CMS Reimbursement for HAI	39
"Never Events" Reimbursement	40
Generating Antibiotics Incentives Now Act (2012)	40
BRAZILIAN REGULATIONS	41
EUROPEAN REGULATIONS	41
Innovative Medicines Initiative (IMI)	41
Implications for Pharmaceutical Manufacturers	41
JAPANESE REGULATIONS	42
CHINESE REGULATIONS	42
CHAPTER 4 HAI PHARMACEUTICAL MARKET	44
<i>TABLE 9 BACTERIA THAT COMMONLY CAUSE HAI</i>	44
PHARMACEUTICALS USED FOR HAI	45
<i>TABLE 10 GLOBAL MARKET FOR HAI PHARMACEUTICALS BY TYPE, THROUGH 2020 (\$ MILLIONS)</i>	46
VIRAL HAI PHARMACEUTICALS	46
<i>TABLE 11 SELECTED VIRAL HAI PHARMACEUTICALS BY NAME, INDICATION AND MANUFACTURER, 2014</i>	46
VIRAL PHARMACEUTICAL MARKET BY COMPANY	47
<i>FIGURE 2 GLOBAL MARKET SHARES OF HEPATITIS, INFLUENZA AND PNEUMONIA PHARMACEUTICALS TO TREAT HAI BY COMPANY, 2014 (%)</i>	47
VIRAL PHARMACEUTICAL MARKET BY CONDITION	48
<i>TABLE 12 GLOBAL MARKET FOR PHARMACEUTICALS TO TREAT VIRAL HAI BY CONDITION, THROUGH 2020 (\$ MILLIONS)</i>	48
<i>FIGURE 3 GLOBAL MARKET SHARE FOR HAI VIRAL PHARMACEUTICALS, BY DISEASE TYPE, 2014 (%)</i>	48
BACTERIAL HAI	49
THE THREAT OF ANTIBIOTIC RESISTANCE	49
THE MICROBIOLOGY OF BACTERIAL RESISTANCE	50
MECHANISMS OF RESISTANCE	50
<i>TABLE 13 ANTIBIOTIC CLASSES AND THEIR MODE OF ACTION</i>	51
METHODS OF RESISTANCE	51
Beta-Lactamase Production	51
Importing Resistance from Other Organisms	52
Alteration of Binding Sites to Circumvent Anti-infective Effectiveness	53

TOPIC	PAGE NO.
Antibiotic Discharge	53
PRIMARY REASONS FOR ANTIBIOTIC RESISTANCE	53
Incomplete Course of Prescribed Medicine	53
Overuse of Broad-Spectrum Antibiotics	53
Antibiotics and Food Production Animals	54
<i>TABLE 14 ANTIBIOTICS APPROVED FOR USE IN FOOD-PRODUCING ANIMALS BY DRUG CLASS, POUNDS USED, AND PERCENTAGE OF TOTAL, 2009 (POUNDS/%)</i>	55
Patient Pressure	55
RESISTANCE BY CLASS OF ANTIBIOTIC	55
<i>TABLE 15 ANTIBIOTIC RESISTANT ORGANISMS AND DRUG CLASSES AFFECTED</i>	56
BACTERIAL HAI PHARMACEUTICALS	56
<i>TABLE 16 SELECTED BACTERIAL HAI PHARMACEUTICALS BY NAME, INDICATION AND MANUFACTURER, 2014</i>	56
CLASSES OF DRUGS	58
Aminoglycosides	58
B-lactam Antibiotics	58
Cephalosporins	58
Glycopeptides	59
Lincosamides	59
Lipopeptides	60
Carbapenems	60
Penicillins	60
Polypeptides	60
Macrolides	61
Quinolones	61
Tetracyclines	61
Sulfonamides	61
Other Formulations	61
GLOBAL MARKET SHARE FOR BACTERIAL PHARMACEUTICALS BY COMPANY	62
<i>FIGURE 4 GLOBAL MARKET SHARES OF HAI BACTERIAL PHARMACEUTICALS BY COMPANY, 2014 (%)</i>	62
BACTERIAL PHARMACEUTICAL MARKET BY TYPE	63
<i>TABLE 17 GLOBAL MARKET FOR PHARMACEUTICALS TO TREAT BACTERIAL HAI, THROUGH 2020 (\$ MILLIONS)</i>	63
FUNGAL HAI PHARMACEUTICALS	63
<i>TABLE 18 SELECT LISTING OF PHARMACEUTICALS TO TREAT FUNGAL INFECTIONS BY NAME, TYPE AND MANUFACTURER, 2014</i>	64
<i>TABLE 19 GLOBAL MARKET FOR PHARMACEUTICALS TO TREAT FUNGAL HAI, THROUGH 2020 (\$ MILLIONS)</i>	64
FUNGAL PHARMACEUTICAL MARKET BY COMPANY	65
<i>FIGURE 5 GLOBAL MARKET SHARES OF PHARMACEUTICALS TO TREAT FUNGAL HAI, BY COMPANY, 2014 (%)</i>	65
GLOBAL OPPORTUNITIES	65
GLOBAL GROWTH RATES FOR PHARMACEUTICALS	66
ROLE OF EMERGING COUNTRIES IN GLOBAL MARKETS	66
PHARMACEUTICAL SALES IN EMERGING NATIONS	66
REGIONAL ANALYSIS	66
GLOBAL MARKET FOR HAI PHARMACEUTICALS	67

TOPIC	PAGE NO.
<i>TABLE 20 GLOBAL MARKET FOR HAI PHARMACEUTICALS BY REGION, THROUGH 2020 (\$ MILLIONS)</i>	67
AMERICAS	67
<i>TABLE 21 AMERICAS MARKET FOR PHARMACEUTICAL PRODUCTS DESIGNED TO MINIMIZE HAI BY REGION, THROUGH 2020 (\$ MILLIONS)</i>	68
<i>TABLE 22 AMERICAS MARKET FOR PHARMACEUTICAL PRODUCTS DESIGNED TO MINIMIZE HAI BY TYPE, THROUGH 2020 (\$ MILLIONS)</i>	68
<i>FIGURE 6 AMERICAS HAI PHARMACEUTICAL MARKET SHARES, BY DISEASE TYPE, 2015 AND 2020 (%)</i>	68
EMRA	69
<i>TABLE 23 EMRA MARKET FOR PHARMACEUTICAL PRODUCTS DESIGNED TO MINIMIZE HAI BY REGION, THROUGH 2020 (\$ MILLIONS)</i>	70
<i>TABLE 24 EMRA MARKET FOR PHARMACEUTICAL PRODUCTS DESIGNED TO MINIMIZE HAI, BY TYPE, THROUGH 2020 (\$ MILLIONS)</i>	70
<i>FIGURE 7 EMRA HAI PHARMACEUTICAL MARKET SHARES BY DISEASE TYPE, 2015 AND 2020 (%)</i>	71
ASIA	72
Japan	72
Hepatitis in Japan	72
China	72
Hepatitis in China	72
Surgical Site Infections in China	72
India	73
Australia	73
<i>TABLE 25 ASIAN MARKET FOR PHARMACEUTICAL PRODUCTS DESIGNED TO MINIMIZE HAI BY REGION, THROUGH 2020 (\$ MILLIONS)</i>	74
<i>TABLE 26 ASIAN MARKET FOR PHARMACEUTICAL PRODUCTS DESIGNED TO MINIMIZE HAI, BY TYPE, THROUGH 2020 (\$ MILLIONS)</i>	74
<i>FIGURE 8 ASIAN HAI PHARMACEUTICAL MARKET SHARES BY DISEASE TYPE, 2015 AND 2020 (%)</i>	74
CHAPTER 5 HAI ENVIRONMENTAL TREATMENT MARKET	77
GLOBAL HAI ENVIRONMENTAL TREATMENT MARKET	77
<i>TABLE 27 GLOBAL MARKET FOR ENVIRONMENTAL PRODUCTS DESIGNED TO MINIMIZE HEALTHCARE-ACQUIRED INFECTIONS BY TYPE, THROUGH 2020 (\$ MILLIONS)</i>	78
AIR TREATMENT	78
ROOM FILTRATION SYSTEMS	78
ROOM PRESSURIZATION	79
HYDROGEN PEROXIDE VAPOR (HPV)	79
ULTRAVIOLET (UV) LIGHT DISINFECTION	80
WATER TREATMENT	80
DESIGN OF SINKS AND OTHER WATER FACILITIES	80
LEVELS OF CLEANING	80
ENVIRONMENTAL CLEANING	80
<i>TABLE 28 SURVIVAL OF HOSPITAL PATHOGENS ON DRY HOSPITAL SURFACES</i>	81
DISINFECTION	81
Levels of Disinfection	82
Disinfectant Drying Time	82
<i>TABLE 29 ADVANTAGES/DISADVANTAGES OF COMMONLY USED DISINFECTANTS</i>	83

TOPIC	PAGE NO.
Cleaning Monitoring	85
Disinfectants	85
Phenolics	85
Oxidizing Agents	85
Halogens	85
Aldehydes	86
Ortho-phthalaldehyde (OPA)	86
Quaternary Ammonium Compounds	86
Bleach	86
Alcohols	86
<i>TABLE 30 GLOBAL MARKET FOR DISINFECTANT PRODUCTS DESIGNED TO MINIMIZE HEALTHCARE-ACQUIRED INFECTIONS, THROUGH 2020 (\$ MILLIONS)</i>	87
Antimicrobial Copper Surface Coatings	87
PATIENT SKIN PREPARATION	87
POVIDONE-IODINE SOLUTIONS	88
CHLOROHEXIDINE GLUCONATE	88
<i>TABLE 31 GLOBAL MARKET FOR PATIENT SKIN PREPARATION DISINFECTANTS, THROUGH 2020 (\$ MILLIONS)</i>	89
STERILIZATION SYSTEMS FOR INFECTION CONTROL	89
<i>TABLE 32 GLOBAL MARKET FOR MEDICAL STERILIZATION PRODUCTS DESIGNED TO MINIMIZE HEALTHCARE-ACQUIRED INFECTIONS, THROUGH 2020 (\$ MILLIONS)</i>	90
FILTRATION	90
<i>TABLE 33 GLOBAL MARKET OF IN-LINE MEDICAL FILTERS USED IN CONJUNCTION WITH MEDICAL ADMINISTRATION OF SOLUTIONS, THROUGH 2020 (\$ MILLIONS)</i>	91
CHEMICAL STERILIZATION	91
<i>TABLE 34 GLOBAL MARKET FOR MEDICAL CHEMICAL STERILIZATION EQUIPMENT AND CONSUMABLES, THROUGH 2020 (\$ MILLIONS)</i>	92
EtO Sterilization	92
Other Types of Chemical Sterilization	93
Hydrogen Peroxide	93
Ozone	93
Chlorine Dioxide	93
Major Manufacturers in Chemical Sterilization	93
STEAM STERILIZATION	94
<i>TABLE 35 GLOBAL MARKET FOR MEDICAL STEAM STERILIZATION EQUIPMENT AND CONSUMABLES, THROUGH 2020 (\$ MILLIONS)</i>	94
<i>TABLE 36 SELECTED MATERIALS THAT RESPOND WELL TO STEAM STERILIZATION</i>	95
Autoclaving	95
Major Players in Heat Sterilization	95
RADIATION STERILIZATION	95
<i>TABLE 37 GLOBAL MARKET FOR RADIATION STERILIZATION PRODUCTS DESIGNED TO MINIMIZE HEALTHCARE-ACQUIRED INFECTIONS BY TYPE, THROUGH 2020 (\$ MILLIONS)</i>	96
Gamma Radiation	96
Medical Uses	97
<i>TABLE 38 MICROBES INACTIVATED BY GAMMA IRRADIATION AND THE AMOUNT OF NECESSARY KGY</i>	97
<i>TABLE 39 MEDICAL GRADE POLYMERS CAPABLE OF TOLERATING GAMMA RADIATION (KGY)</i>	98

TOPIC	PAGE NO.
Electron-Beam Radiation	98
REGIONAL ANALYSIS	99
<i>TABLE 40 GLOBAL MARKET FOR ENVIRONMENTAL PRODUCTS/ EQUIPMENT TO CONTROL HAI, BY REGION, THROUGH 2020 (\$ MILLIONS)</i>	99
AMERICAS	99
<i>TABLE 41 AMERICAS MARKET FOR ENVIRONMENTAL PRODUCTS/ EQUIPMENT TO CONTROL HAI BY REGION, THROUGH 2020 (\$ MILLIONS)</i>	99
<i>TABLE 42 AMERICAS MARKET FOR ENVIRONMENTAL PRODUCTS DESIGNED TO MINIMIZE HEALTHCARE-ACQUIRED INFECTIONS BY PRODUCT TYPE, THROUGH 2020 (\$ MILLIONS)</i>	100
EMRA	100
Patient Skin Preparation Solutions	100
EMRA Market for Environmental Products/Equipment	101
<i>TABLE 43 EMRA MARKET FOR ENVIRONMENTAL PRODUCTS/ EQUIPMENT TO CONTROL HAI BY REGION, THROUGH 2020 (\$ MILLIONS)</i>	101
<i>TABLE 44 EMRA MARKET FOR ENVIRONMENTAL PRODUCTS DESIGNED TO MINIMIZE HEALTHCARE-ACQUIRED INFECTIONS, THROUGH 2020 (\$ MILLIONS)</i>	102
ASIA	102
<i>TABLE 45 ASIAN MARKET FOR ENVIRONMENTAL PRODUCTS/ EQUIPMENT TO CONTROL HAI, THROUGH 2020 (\$ MILLIONS)</i>	103
<i>TABLE 46 ASIAN MARKET FOR ENVIRONMENTAL PRODUCTS DESIGNED TO MINIMIZE HEALTHCARE-ACQUIRED INFECTIONS, THROUGH 2020 (\$ MILLIONS)</i>	103
CHAPTER 6 HAI MEDICAL DEVICES: CATHETERS, PATIENT VENTILATION SYSTEMS AND IN-LINE STERILIZATION FILTERS	105
<i>TABLE 47 GLOBAL MARKET FOR MEDICAL DEVICES THAT ARE DESIGNED TO MINIMIZE HAI, THROUGH 2020 (\$ MILLIONS)</i>	105
ANTIMICROBIAL COATINGS	105
CATHETERS	105
<i>FIGURE 9 MAJOR NOSOCOMIAL INFECTIONS IN U.S. ICU BY TYPE AND PERCENT (%)</i>	106
CATHETER COATINGS	107
Common Antimicrobial Coatings	107
Nitrofurazone	107
Minocycline/Rifampin	107
Silver Coating	108
Combination Minocycline-Rifampin-Chlorhexidine Catheters	108
SURFACE-MODIFIED CATHETER	108
GLOBAL HAI CATHETER MARKET	109
<i>TABLE 48 GLOBAL MARKET FOR CATHETERS WITH ANTIMICROBIAL PROPERTIES BY TYPE, THROUGH 2020 (\$ MILLIONS)</i>	109
<i>FIGURE 10 PROJECTED HAI CATHETER MARKET SHARES BY TYPE, 2015 AND 2020 (%)</i>	109
URINARY TRACT CATHETERS	110
CENTRAL VENOUS CATHETERS	111
Dialysis Catheters	111
Catheter-Related Bloodstream Infections (CRBSI)	111
PERIPHERALLY INSERTED CENTRAL VENOUS CATHETERS (PICC)	112
MARKET OPPORTUNITIES FOR CATHETER MANUFACTURERS	112
<i>TABLE 49 KEY MANUFACTURERS OF ANTIBIOTIC-COATED CATHETERS BY NAME, LOCATION AND PRODUCTS, 2014</i>	113

TOPIC	PAGE NO.
CATHETER GROWTH IN REGIONAL MARKETS	113
<i>TABLE 50 GLOBAL HAI CATHETER MARKET BY REGION, THROUGH 2020 (\$ MILLIONS)</i>	114
<i>FIGURE 11 PROJECTED GLOBAL HAI CATHETER MARKET SHARES BY REGION, 2015 AND 2020 (%)</i>	114
PATIENT VENTILATION DEVICES	115
<i>TABLE 51 GLOBAL MARKET FOR PATIENT VENTILATION PRODUCTS, THROUGH 2020 (\$ MILLIONS)</i>	115
TYPES OF VENTILATION DEVICES	116
Noninvasive Ventilators	116
PATIENT VENTILATION MARKET	116
<i>TABLE 52 GLOBAL MARKET FOR NONINVASIVE VENTILATION SYSTEMS FOR USE WITH HAI-INFECTED PATIENTS, THROUGH 2020 (\$ MILLIONS)</i>	117
ENDOTRACHEAL TUBES AND VENTILATION SYSTEMS	117
Coated Endotracheal Tubes	117
Tapered Endotracheal Tubes	117
<i>TABLE 53 GLOBAL MARKET FOR COATED ENDOTRACHEAL TUBES DESIGNED TO MINIMIZE VAP, THROUGH 2020 (\$ MILLIONS)</i>	118
IN-LINE STERILE IV FILTRATION	118
<i>TABLE 54 GLOBAL STERILE IV FILTER MARKET, THROUGH 2020 (\$ MILLIONS)</i>	119
REGIONAL ANALYSIS	119
<i>TABLE 55 GLOBAL MARKET FOR PATIENT INFECTION CONTROL DEVICES BY REGION, THROUGH 2020 (\$ MILLIONS)</i>	119
<i>FIGURE 12 GLOBAL HAI PATIENT INFECTION CONTROL DEVICES MARKET SHARES BY REGION, 2015 AND 2020 (%)</i>	119
THE AMERICAS	121
<i>TABLE 56 AMERICAS MARKET FOR INFECTION CONTROL DEVICES DESIGNED TO MINIMIZE HAI, BY REGION, THROUGH 2020 (\$ MILLIONS)</i>	121
<i>TABLE 57 AMERICAS MARKET FOR CATHETERS, PATIENT VENTILATION SYSTEMS AND IN-LINE STERILE FILTERS, THROUGH 2020 (\$ MILLIONS)</i>	122
EMRA	122
<i>TABLE 58 EMRA MARKET FOR INFECTION CONTROL DEVICES DESIGNED TO MINIMIZE HAI, BY REGION, THROUGH 2020 (\$ MILLIONS)</i>	122
<i>TABLE 59 EMRA MARKET FOR CATHETERS, PATIENT VENTILATION SYSTEMS AND IN-LINE STERILE FILTERS, THROUGH 2020 (\$ MILLIONS)</i>	123
ASIA	123
<i>TABLE 60 ASIAN MARKET FOR INFECTION CONTROL DEVICES DESIGNED TO MINIMIZE HAI BY REGION, THROUGH 2020 (\$ MILLIONS)</i>	124
<i>TABLE 61 ASIAN MARKET FOR CATHETERS, PATIENT VENTILATION SYSTEMS AND IN-LINE STERILE FILTERS, THROUGH 2020 (\$ MILLIONS)</i>	124
CHAPTER 7 CURRENT RESEARCH, EMERGING THERAPIES AND MARKET OPPORTUNITIES	126
EMERGING RESEARCH	126
ANTIBACTERIAL SURFACES	126
FIM-D	126
BROAD SPECTRUM ANTIVIRAL	127
" NANOTRAPS "	128
FECAL PILLS TO TREAT C. DIFFICILE	128
PHARMACEUTICAL TREATMENT PRODUCT PIPELINE	129

TOPIC	PAGE NO.
<i>TABLE 62 HAI PHARMACEUTICAL PRODUCT PIPELINE</i>	129
<i>FIGURE 13 MARKET SHARE BY TYPE OF PHARMACEUTICAL COMPOUND IN DEVELOPMENT, 2014 (%)</i>	132
PHARMACEUTICAL RESEARCH	133
BACTERIAL INFECTIONS: PRODUCTS IN DEVELOPMENT	133
Achaogen	133
Melinata Therapeutics	134
GlaxoSmithKline (GSK)	134
Polyphor	134
The Medicines Company	134
Basilea Pharmaceuticals	135
Cempra Pharmaceuticals	135
Nabriva Therapeutics	135
Furiex Pharmaceuticals	136
Merck	136
Toyama Chemical	137
Crestone Pharma	137
Theravance Biopharma	137
Paratek Pharmaceuticals	138
AstraZeneca	138
Daiichi Sankyo	138
Roche	138
VIRAL INFECTIONS: PRODUCTS IN DEVELOPMENT	138
BioCryst Pharmaceuticals	138
Boehringer Ingelheim	139
Roche	139
Merck	139
Toyama Chemical	139
Gilead Sciences	139
Vertex	140
Bristol-Myers Squibb	140
OPPORTUNITIES/CHALLENGES FOR HAI INDUSTRY	140
CHALLENGES	141
PHARMACEUTICAL MARKET OPPORTUNITIES/CHALLENGES	141
Patent Expiry	141
<i>TABLE 63 SELECTED HAI-RELATED PHARMACEUTICAL PATENT EXPIRATIONS, 2004-2024</i>	142
Pipeline Limitations	142
Regulatory Restrictions	142
Generic Competition	143
THE IMPACT OF DEMOGRAPHIC CHANGES	143
DEMOGRAPHIC CHANGES IN THE U.S.	143
DEMOGRAPHIC CHANGES OUTSIDE THE U.S.	143
CHAPTER 8 PATENTS	145
<i>TABLE 64 NUMBER OF SELECTED PATENTS BY TYPE, JANUARY 2010 THROUGH FEBRUARY 2015</i>	145
PATENTS BY DATE OF ISSUE	145

TOPIC	PAGE NO.
<i>TABLE 65 PHARMACEUTICAL PATENTS BY DATE OF ISSUE, JANUARY 2010 THROUGH MARCH 2015</i>	146
<i>TABLE 66 ENVIRONMENTAL PATENTS* BY DATE OF ISSUE, JANUARY 2010 THROUGH MARCH 2015</i>	146
<i>TABLE 67 MEDICAL DEVICE PATENTS BY DATE OF ISSUE, JANUARY 2010 THROUGH MARCH 2015</i>	146
NUMBER OF PATENTS BY MANUFACTURER	146
<i>TABLE 68 NUMBER OF PATENTS BY MANUFACTURER, JANUARY 2010 THROUGH FEBRUARY 2015</i>	147
PHARMACEUTICALS	151
BACTERIAL PHARMACEUTICAL PATENTS	151
<i>TABLE 69 PATENTS ON BACTERIAL PHARMACEUTICALS, SEPTEMBER 2010 THROUGH MARCH 2015</i>	151
FUNGAL PHARMACEUTICAL PATENTS	166
<i>TABLE 70 PATENTS ON FUNGAL PHARMACEUTICALS, SEPTEMBER 2010 THROUGH FEBRUARY 2015</i>	166
VIRAL PHARMACEUTICAL PATENTS	167
<i>TABLE 71 PATENTS ON VIRAL PHARMACEUTICALS, JANUARY 2011 THROUGH MARCH 2015</i>	167
ENVIRONMENTAL CONTROLS	179
AIR FILTRATION	179
<i>TABLE 72 PATENTS ON AIR FILTRATION, FEB 2011-MARCH 2013</i>	180
WATER FILTRATION	182
<i>TABLE 73 PATENTS ON WATER TREATMENT, SEPTEMBER 2010 TO MARCH 2014</i>	182
SOLID WASTE TREATMENT	183
<i>TABLE 74 PATENTS ON SOLID WASTE TREATMENT, APRIL 2011 THROUGH DECEMBER 2014</i>	184
SURFACE DISINFECTANTS	185
<i>TABLE 75 PATENTS ON SURFACE DISINFECTANTS, JANUARY 2010 TO DECEMBER 2014</i>	185
PATENTS FOR PATIENT DISINFECTION	191
<i>TABLE 76 PATENTS ON PATIENT DISINFECTANTS, DECEMBER 2010 TO APRIL 2013</i>	192
MEDICAL DEVICES	193
CATHETERS	193
<i>TABLE 77 PATENTS ON CATHETERS, JULY 2010 TO FEBRUARY 2015</i>	193
ANTIMICROBIAL COATINGS	197
<i>TABLE 78 PATENTS ON ANTIMICROBIAL COATINGS, AUGUST 2010 THROUGH JANUARY 2015</i>	197
CHAPTER 9 COMPANY DIRECTORY	210
PHARMACEUTICALS	210
ABBOTT LABORATORIES	210
Business Overview	210
Products	210
<i>TABLE 79 ABBOTT HAI PRODUCTS</i>	210
ABBVIE INC.	210
Business overview	211
Products	211
<i>TABLE 80 ABBVIE HAI PRODUCTS</i>	211

TOPIC	PAGE NO.
ACHAOGEN INC.	211
Business Overview	211
ACTAVIS PLC	211
Business Overview	212
Products	212
<i>TABLE 81 ACTAVIS HAI PRODUCTS</i>	212
ASTELLAS PHARMA INC.	212
Business Overview	212
Products	213
<i>TABLE 82 ASTELLAS HAI PRODUCTS</i>	213
ASTRAZENECA PLC	213
Business Overview	213
Products	213
<i>TABLE 83 ASTRAZENECA HAI PRODUCTS</i>	213
B. BRAUN MELSUNGEN	214
Business Overview	214
Products	214
<i>TABLE 84 B. BRAUN HAI PRODUCTS</i>	214
BACTIGUARD AB	214
Business Overview	214
Products	215
BASILEA PHARMACEUTICA LTD.	215
Business Overview	215
Products	215
<i>TABLE 85 BASILEA HAI PRODUCTS</i>	215
BAXTER INTERNATIONAL	216
Business Overview	216
BAYER AG (MILES-BAYER)	216
Business Overview	216
Products	217
<i>TABLE 86 BAYER HAI PRODUCTS</i>	217
BRISTOL-MYERS SQUIBB	217
Business Overview	217
Products	217
<i>TABLE 87 BRISTOL MYERS SQUIBB HAI PRODUCTS</i>	217
GILEAD SCIENCES	218
Business Overview	218
Products	218
<i>TABLE 88 GILEAD SCIENCES HAI PRODUCTS</i>	218
GLAXOSMITHKLINE	218
Business Overview	218
Products	219
<i>TABLE 89 GLAXOSMITHKLINE HAI PRODUCTS</i>	219
JANSSEN THERAPEUTICS (FORMERLY TIBOTEC THERAPEUTICS)	219
Business Overview	219
Products	219
<i>TABLE 90 JANSSEN THERAPEUTICS HAI PRODUCTS</i>	219

TOPIC	PAGE NO.
JOHNSON & JOHNSON	220
Business Overview	220
Products	220
<i>TABLE 91 JOHNSON & JOHNSON HAI PRODUCTS</i>	220
MELINTA THERAPEUTICS (FORMERLY RIB-X PHARMACEUTICALS)	220
Business Overview	220
MERCK	221
Business Overview	221
Products	221
<i>TABLE 92 MERCK HAI PRODUCTS</i>	221
NOVARTIS PHARMACEUTICALS	222
Business Overview	222
Products	222
<i>TABLE 93 NOVARTIS HAI PRODUCTS</i>	222
PARATEK PHARMACEUTICALS	222
Business Overview	222
PFIZER	223
Business Overview	223
Products	223
<i>TABLE 94 PFIZER HAI PRODUCTS</i>	223
ROCHE PHARMACEUTICALS	224
Business Overview	224
Products	224
<i>TABLE 95 ROCHE HAI PHARMACEUTICAL PRODUCTS</i>	224
SHIRE PLC	224
Business Overview	224
Products	225
<i>TABLE 96 SHIRE HAI PHARMACEUTICAL PRODUCTS</i>	225
SUN PHARMA	225
Business Overview	225
Products	226
<i>TABLE 97 SUN PHARMA HAI PHARMACEUTICAL PRODUCTS</i>	226
TETRAPHASE PHARMACEUTICALS	226
Business Overview	227
THE MEDICINE COMPANY	227
Business Overview	227
Products	227
<i>TABLE 98 THE MEDICINE COMPANY HAI PHARMACEUTICAL PRODUCTS</i>	227
THERAVANCE BIOPHARMA	227
Business Overview	228
Products	228
<i>TABLE 99 THERAVANCE HAI PRODUCTS</i>	228
TOYAMA CHEMICAL CO. LTD.	228
Business Overview	228
Products	228
<i>TABLE 100 TOYAMA CHEMICAL HAI PRODUCTS</i>	228
VENUS REMEDIES LTD.	229

TOPIC	PAGE NO.
Business Overview	229
Products	229
<i>TABLE 101 VENUS REMEDIES HAI PRODUCTS</i>	229
ENVIRONMENTAL PRODUCTS	229
3M HEALTHCARE, MEDICAL DIVISION	229
Business Overview	230
Products	230
ADVANCED STERILIZATION PRODUCTS	230
Business Overview	230
Products	230
ANDERSEN PRODUCTS INC.	231
Business Overview	231
Products	231
BELIMED	231
Business Overview	231
Products	231
BETA STAR LIFE SCIENCE EQUIPMENT (R-V INDUSTRIES)	231
Business Overview	232
Products	232
BIOQUELL UK LTD.	232
Business Overview	232
Products	232
CONSOLIDATED STERILIZER SYSTEMS	232
Business Overview	233
Products	233
E-BEAM SERVICES INC.	233
Business Overview	233
Products	233
ECOLAB	233
Business Overview	233
Products	234
EOS SURFACES LLC	234
Business Overview	234
Product	234
GETINGE USA INC.	234
Business Overview	235
Products	235
IBA GROUP	235
Business Overview	235
Products	235
LTE SCIENTIFIC LTD.	235
Business Overview	236
Products	236
LUMALIER	236
Business Overview	236
Products	236
MESA LABORATORIES	236

TOPIC	PAGE NO.
Business Overview	236
Products	237
METREX RESEARCH	237
Business Overview	237
Products	237
NORION INC. (SEE STERIGENICS)	237
PRIMUS STERILIZER CO. INC.	238
Business Overview	238
Products	238
RUHOF CORP.	238
Business Overview	238
Products	238
SANOSIL INTERNATIONAL	239
Business Overview	239
Products	239
SEALED AIR CORP. (DIVERSEY CARE)	239
Business Overview	239
Products	239
STERIGENICS INTERNATIONAL INC.	240
Business Overview	240
Products	240
STERIS CORP.	240
Business Overview	240
Products	241
SYNERGY HEALTH STERILISATION UK LTD	241
Business Overview	241
Products	241
TERRAGENE SRL	242
Business Overview	242
Products	242
TSO3	242
Business Overview	242
Products	242
TUTTNAUER USA CO. LTD.	243
Business Overview	243
Products	243
ULTRAVIOLET DEVICES INC.	243
Business Overview	243
Products	243
XENEX DISINFECTION SERVICES	243
Business Overview	244
Products	244
INFECTION CONTROL PRODUCTS/DEVICES	244
B BRAUN MELSUNGEN AG	244
Business Overview	244
Products	244
BECTON DICKINSON	245

TOPIC	PAGE NO.
Business Overview	245
Products	245
CANTEL MEDICAL CORP.	246
Business Overview	246
Products	246
CAREFUSION CORP.	246
Business Overview	246
Products	246
CLOROX CO.	247
Business Overview	247
Products	247
COLOPLAST GROUP	247
Business Overview	247
Products	247
COOK MEDICAL	248
Business Overview	248
Products	248
COVIDIEN PLC (MEDTRONIC)	248
Business Overview	248
Products	248
C.R. BARD	249
Business Overview	249
Products	249
HALYARD HEALTH	249
Business Overview	249
Products	249
ONDINE BIOMEDICAL INC.	250
Business Overview	250
Products	250
ROCHESTER MEDICAL LTD.	250
Business Overview	250
Products	251
SCHULKE & MAYR GMBH	251
Business Overview	251
Products	251
TELEFLEX MEDICAL	251
Business Overview	251
Products	251
WELCH ALLYN INC.	252
Business Overview	252
Products	252

LIST OF TABLES

TABLE HEADING	PAGE NO.
SUMMARY TABLE GLOBAL MARKET FOR SELECTED HAI TREATMENTS, THROUGH 2020 (\$ MILLIONS)	8
TABLE 1 CAUSES AND TYPES OF MOST COMMON HEALTHCARE-ACQUIRED INFECTIONS	13
TABLE 2 SELECTED RESPONSIBILITIES OF INFECTION CONTROL TEAM MEMBERS	24
TABLE 3 MAIN STEPS AND COMPONENTS IN DEVELOPING AN EFFECTIVE INFECTION CONTROL SURVEILLANCE SYSTEM	26
TABLE 4 CDC MEASURES FOR PREVENTION OF HEALTHCARE-ACQUIRED INFECTIONS	30
TABLE 5 PERCENTAGE DECREASE IN HAI IN U.S. HOSPITAL SETTINGS, 2008-2013 (%)	32
TABLE 6 ESTIMATED COSTS OF HAI IN U.S. HOSPITALS, 2012 (PER PATIENT OCCURRENCE) (\$)	33
TABLE 7 SELECTED MERGERS AND/OR ACQUISITIONS, 2010-2015 (\$ MILLIONS)	35
TABLE 8 PROCESS OF CREATING DRUG TREATMENTS IN THE U.S.	37
TABLE 9 BACTERIA THAT COMMONLY CAUSE HAI	44
TABLE 10 GLOBAL MARKET FOR HAI PHARMACEUTICALS BY TYPE, THROUGH 2020 (\$ MILLIONS)	46
TABLE 11 SELECTED VIRAL HAI PHARMACEUTICALS BY NAME, INDICATION AND MANUFACTURER, 2014	46
TABLE 12 GLOBAL MARKET FOR PHARMACEUTICALS TO TREAT VIRAL HAI BY CONDITION, THROUGH 2020 (\$ MILLIONS)	48
TABLE 13 ANTIBIOTIC CLASSES AND THEIR MODE OF ACTION	51
TABLE 14 ANTIBIOTICS APPROVED FOR USE IN FOOD-PRODUCING ANIMALS BY DRUG CLASS, POUNDS USED, AND PERCENTAGE OF TOTAL, 2009 (POUNDS/%)	55
TABLE 15 ANTIBIOTIC RESISTANT ORGANISMS AND DRUG CLASSES AFFECTED	56
TABLE 16 SELECTED BACTERIAL HAI PHARMACEUTICALS BY NAME, INDICATION AND MANUFACTURER, 2014	56
TABLE 17 GLOBAL MARKET FOR PHARMACEUTICALS TO TREAT BACTERIAL HAI, THROUGH 2020 (\$ MILLIONS)	63
TABLE 18 SELECT LISTING OF PHARMACEUTICALS TO TREAT FUNGAL INFECTIONS BY NAME, TYPE AND MANUFACTURER, 2014	64
TABLE 19 GLOBAL MARKET FOR PHARMACEUTICALS TO TREAT FUNGAL HAI, THROUGH 2020 (\$ MILLIONS)	64
TABLE 20 GLOBAL MARKET FOR HAI PHARMACEUTICALS BY REGION, THROUGH 2020 (\$ MILLIONS)	67
TABLE 21 AMERICAS MARKET FOR PHARMACEUTICAL PRODUCTS DESIGNED TO MINIMIZE HAI BY REGION, THROUGH 2020 (\$ MILLIONS)	68
TABLE 22 AMERICAS MARKET FOR PHARMACEUTICAL PRODUCTS DESIGNED TO MINIMIZE HAI BY TYPE, THROUGH 2020 (\$ MILLIONS)	68
TABLE 23 EMRA MARKET FOR PHARMACEUTICAL PRODUCTS DESIGNED TO MINIMIZE HAI BY REGION, THROUGH 2020 (\$ MILLIONS)	70
TABLE 24 EMRA MARKET FOR PHARMACEUTICAL PRODUCTS DESIGNED TO MINIMIZE HAI, BY TYPE, THROUGH 2020 (\$ MILLIONS)	70
TABLE 25 ASIAN MARKET FOR PHARMACEUTICAL PRODUCTS DESIGNED TO MINIMIZE HAI BY REGION, THROUGH 2020 (\$ MILLIONS)	74
TABLE 26 ASIAN MARKET FOR PHARMACEUTICAL PRODUCTS DESIGNED TO MINIMIZE HAI, BY TYPE, THROUGH 2020 (\$ MILLIONS)	74
TABLE 27 GLOBAL MARKET FOR ENVIRONMENTAL PRODUCTS DESIGNED TO MINIMIZE HEALTHCARE-ACQUIRED INFECTIONS BY TYPE, THROUGH 2020 (\$ MILLIONS)	78
TABLE 28 SURVIVAL OF HOSPITAL PATHOGENS ON DRY HOSPITAL SURFACES	81

TABLE HEADING	PAGE NO.
TABLE 29 ADVANTAGES/DISADVANTAGES OF COMMONLY USED DISINFECTANTS	83
TABLE 30 GLOBAL MARKET FOR DISINFECTANT PRODUCTS DESIGNED TO MINIMIZE HEALTHCARE-ACQUIRED INFECTIONS, THROUGH 2020 (\$ MILLIONS)	87
TABLE 31 GLOBAL MARKET FOR PATIENT SKIN PREPARATION DISINFECTANTS, THROUGH 2020 (\$ MILLIONS)	89
TABLE 32 GLOBAL MARKET FOR MEDICAL STERILIZATION PRODUCTS DESIGNED TO MINIMIZE HEALTHCARE-ACQUIRED INFECTIONS, THROUGH 2020 (\$ MILLIONS)	90
TABLE 33 GLOBAL MARKET OF IN-LINE MEDICAL FILTERS USED IN CONJUNCTION WITH MEDICAL ADMINISTRATION OF SOLUTIONS, THROUGH 2020 (\$ MILLIONS)	91
TABLE 34 GLOBAL MARKET FOR MEDICAL CHEMICAL STERILIZATION EQUIPMENT AND CONSUMABLES, THROUGH 2020 (\$ MILLIONS)	92
TABLE 35 GLOBAL MARKET FOR MEDICAL STEAM STERILIZATION EQUIPMENT AND CONSUMABLES, THROUGH 2020 (\$ MILLIONS)	94
TABLE 36 SELECTED MATERIALS THAT RESPOND WELL TO STEAM STERILIZATION	95
TABLE 37 GLOBAL MARKET FOR RADIATION STERILIZATION PRODUCTS DESIGNED TO MINIMIZE HEALTHCARE-ACQUIRED INFECTIONS BY TYPE, THROUGH 2020 (\$ MILLIONS)	96
TABLE 38 MICROBES INACTIVATED BY GAMMA IRRADIATION AND THE AMOUNT OF NECESSARY KGY	97
TABLE 39 MEDICAL GRADE POLYMERS CAPABLE OF TOLERATING GAMMA RADIATION (KGY)	98
TABLE 40 GLOBAL MARKET FOR ENVIRONMENTAL PRODUCTS/ EQUIPMENT TO CONTROL HAI, BY REGION, THROUGH 2020 (\$ MILLIONS)	99
TABLE 41 AMERICAS MARKET FOR ENVIRONMENTAL PRODUCTS/ EQUIPMENT TO CONTROL HAI BY REGION, THROUGH 2020 (\$ MILLIONS)	99
TABLE 42 AMERICAS MARKET FOR ENVIRONMENTAL PRODUCTS DESIGNED TO MINIMIZE HEALTHCARE-ACQUIRED INFECTIONS BY PRODUCT TYPE, THROUGH 2020 (\$ MILLIONS)	100
TABLE 43 EMRA MARKET FOR ENVIRONMENTAL PRODUCTS/ EQUIPMENT TO CONTROL HAI BY REGION, THROUGH 2020 (\$ MILLIONS)	101
TABLE 44 EMRA MARKET FOR ENVIRONMENTAL PRODUCTS DESIGNED TO MINIMIZE HEALTHCARE-ACQUIRED INFECTIONS, THROUGH 2020 (\$ MILLIONS)	102
TABLE 45 ASIAN MARKET FOR ENVIRONMENTAL PRODUCTS/ EQUIPMENT TO CONTROL HAI, THROUGH 2020 (\$ MILLIONS)	103
TABLE 46 ASIAN MARKET FOR ENVIRONMENTAL PRODUCTS DESIGNED TO MINIMIZE HEALTHCARE-ACQUIRED INFECTIONS, THROUGH 2020 (\$ MILLIONS)	103
TABLE 47 GLOBAL MARKET FOR MEDICAL DEVICES THAT ARE DESIGNED TO MINIMIZE HAI, THROUGH 2020 (\$ MILLIONS)	105
TABLE 48 GLOBAL MARKET FOR CATHETERS WITH ANTIMICROBIAL PROPERTIES BY TYPE, THROUGH 2020 (\$ MILLIONS)	109
TABLE 49 KEY MANUFACTURERS OF ANTIBIOTIC-COATED CATHETERS BY NAME, LOCATION AND PRODUCTS, 2014	113
TABLE 50 GLOBAL HAI CATHETER MARKET BY REGION, THROUGH 2020 (\$ MILLIONS)	114
TABLE 51 GLOBAL MARKET FOR PATIENT VENTILATION PRODUCTS, THROUGH 2020 (\$ MILLIONS)	115
TABLE 52 GLOBAL MARKET FOR NONINVASIVE VENTILATION SYSTEMS FOR USE WITH HAI-INFECTED PATIENTS, THROUGH 2020 (\$ MILLIONS)	117
TABLE 53 GLOBAL MARKET FOR COATED ENDOTRACHEAL TUBES DESIGNED TO MINIMIZE VAP, THROUGH 2020 (\$ MILLIONS)	118
TABLE 54 GLOBAL STERILE IV FILTER MARKET, THROUGH 2020 (\$ MILLIONS)	119
TABLE 55 GLOBAL MARKET FOR PATIENT INFECTION CONTROL DEVICES BY REGION, THROUGH 2020 (\$ MILLIONS)	119

TABLE HEADING	PAGE NO.
TABLE 56 AMERICAS MARKET FOR INFECTION CONTROL DEVICES DESIGNED TO MINIMIZE HAI, BY REGION, THROUGH 2020 (\$ MILLIONS)	121
TABLE 57 AMERICAS MARKET FOR CATHETERS, PATIENT VENTILATION SYSTEMS AND IN-LINE STERILE FILTERS, THROUGH 2020 (\$ MILLIONS)	122
TABLE 58 EMRA MARKET FOR INFECTION CONTROL DEVICES DESIGNED TO MINIMIZE HAI, BY REGION, THROUGH 2020 (\$ MILLIONS)	122
TABLE 59 EMRA MARKET FOR CATHETERS, PATIENT VENTILATION SYSTEMS AND IN-LINE STERILE FILTERS, THROUGH 2020 (\$ MILLIONS)	123
TABLE 60 ASIAN MARKET FOR INFECTION CONTROL DEVICES DESIGNED TO MINIMIZE HAI BY REGION, THROUGH 2020 (\$ MILLIONS)	124
TABLE 61 ASIAN MARKET FOR CATHETERS, PATIENT VENTILATION SYSTEMS AND IN-LINE STERILE FILTERS, THROUGH 2020 (\$ MILLIONS)	124
TABLE 62 HAI PHARMACEUTICAL PRODUCT PIPELINE	129
TABLE 63 SELECTED HAI-RELATED PHARMACEUTICAL PATENT EXPIRATIONS, 2004-2024	142
TABLE 64 NUMBER OF SELECTED PATENTS BY TYPE, JANUARY 2010 THROUGH FEBRUARY 2015	145
TABLE 65 PHARMACEUTICAL PATENTS BY DATE OF ISSUE, JANUARY 2010 THROUGH MARCH 2015	146
TABLE 66 ENVIRONMENTAL PATENTS* BY DATE OF ISSUE, JANUARY 2010 THROUGH MARCH 2015	146
TABLE 67 MEDICAL DEVICE PATENTS BY DATE OF ISSUE, JANUARY 2010 THROUGH MARCH 2015	146
TABLE 68 NUMBER OF PATENTS BY MANUFACTURER, JANUARY 2010 THROUGH FEBRUARY 2015	147
TABLE 69 PATENTS ON BACTERIAL PHARMACEUTICALS, SEPTEMBER 2010 THROUGH MARCH 2015	151
TABLE 70 PATENTS ON FUNGAL PHARMACEUTICALS, SEPTEMBER 2010 THROUGH FEBRUARY 2015	166
TABLE 71 PATENTS ON VIRAL PHARMACEUTICALS, JANUARY 2011 THROUGH MARCH 2015	167
TABLE 72 PATENTS ON AIR FILTRATION, FEB 2011-MARCH 2013	180
TABLE 73 PATENTS ON WATER TREATMENT, SEPTEMBER 2010 TO MARCH 2014	182
TABLE 74 PATENTS ON SOLID WASTE TREATMENT, APRIL 2011 THROUGH DECEMBER 2014	184
TABLE 75 PATENTS ON SURFACE DISINFECTANTS, JANUARY 2010 TO DECEMBER 2014	185
TABLE 76 PATENTS ON PATIENT DISINFECTANTS, DECEMBER 2010 TO APRIL 2013	192
TABLE 77 PATENTS ON CATHETERS, JULY 2010 TO FEBRUARY 2015	193
TABLE 78 PATENTS ON ANTIMICROBIAL COATINGS, AUGUST 2010 THROUGH JANUARY 2015	197
TABLE 79 ABBOTT HAI PRODUCTS	210
TABLE 80 ABBVIE HAI PRODUCTS	211
TABLE 81 ACTAVIS HAI PRODUCTS	212
TABLE 82 ASTELLAS HAI PRODUCTS	213
TABLE 83 ASTRAZENECA HAI PRODUCTS	213
TABLE 84 B. BRAUN HAI PRODUCTS	214
TABLE 85 BASILEA HAI PRODUCTS	215
TABLE 86 BAYER HAI PRODUCTS	217
TABLE 87 BRISTOL MYERS SQUIBB HAI PRODUCTS	217
TABLE 88 GILEAD SCIENCES HAI PRODUCTS	218

TABLE HEADING	PAGE NO.
TABLE 89 GLAXOSMITHKLINE HAI PRODUCTS	219
TABLE 90 JANSSEN THERAPEUTICS HAI PRODUCTS	219
TABLE 91 JOHNSON & JOHNSON HAI PRODUCTS	220
TABLE 92 MERCK HAI PRODUCTS	221
TABLE 93 NOVARTIS HAI PRODUCTS	222
TABLE 94 PFIZER HAI PRODUCTS	223
TABLE 95 ROCHE HAI PHARMACEUTICAL PRODUCTS	224
TABLE 96 SHIRE HAI PHARMACEUTICAL PRODUCTS	225
TABLE 97 SUN PHARMA HAI PHARMACEUTICAL PRODUCTS	226
TABLE 98 THE MEDICINE COMPANY HAI PHARMACEUTICAL PRODUCTS	227
TABLE 99 THERAVANCE HAI PRODUCTS	228
TABLE 100 TOYAMA CHEMICAL HAI PRODUCTS	228
TABLE 101 VENUS REMEDIES HAI PRODUCTS	229

LIST OF FIGURES

FIGURE TITLE	PAGE NO.
SUMMARY FIGURE GLOBAL MARKET SHARES OF HAI TREATMENTS BY GEOGRAPHICAL AREA, 2015 AND 2020 (%)	8
FIGURE 1 OCCURRENCE OF HAI IN U.S. HOSPITALS BY TYPE, 2011 (%)	27
FIGURE 2 GLOBAL MARKET SHARES OF HEPATITIS, INFLUENZA AND PNEUMONIA PHARMACEUTICALS TO TREAT HAI BY COMPANY, 2014 (%)	47
FIGURE 3 GLOBAL MARKET SHARE FOR HAI VIRAL PHARMACEUTICALS, BY DISEASE TYPE, 2014 (%)	48
FIGURE 4 GLOBAL MARKET SHARES OF HAI BACTERIAL PHARMACEUTICALS BY COMPANY, 2014 (%)	62
FIGURE 5 GLOBAL MARKET SHARES OF PHARMACEUTICALS TO TREAT FUNGAL HAI, BY COMPANY, 2014 (%)	65
FIGURE 6 AMERICAS HAI PHARMACEUTICAL MARKET SHARES, BY DISEASE TYPE, 2015 AND 2020 (%)	68
FIGURE 7 EMRA HAI PHARMACEUTICAL MARKET SHARES BY DISEASE TYPE, 2015 AND 2020 (%)	71
FIGURE 8 ASIAN HAI PHARMACEUTICAL MARKET SHARES BY DISEASE TYPE, 2015 AND 2020 (%)	74
FIGURE 9 MAJOR NOSOCOMIAL INFECTIONS IN U.S. ICU BY TYPE AND PERCENT (%)	106
FIGURE 10 PROJECTED HAI CATHETER MARKET SHARES BY TYPE, 2015 AND 2020 (%)	109
FIGURE 11 PROJECTED GLOBAL HAI CATHETER MARKET SHARES BY REGION, 2015 AND 2020 (%)	114
FIGURE 12 GLOBAL HAI PATIENT INFECTION CONTROL DEVICES MARKET SHARES BY REGION, 2015 AND 2020 (%)	119
FIGURE 13 MARKET SHARE BY TYPE OF PHARMACEUTICAL COMPOUND IN DEVELOPMENT, 2014 (%)	132